Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Brentuximab Vedotin Following Allogeneic Stem Cell Transplantation for Hodgkin Lymphoma
2017-002444-32Phase 2Terminated
- Sponsor
- CHU Caen Normandie
- Start
- Dec 2017
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in Hodgkin lymphoma (HL), sponsored by CHU Caen Normandie. Primary endpoint: Cumulative incidence of relapse or progression at 12 months after allo-SCT. Started Dec 2017; status: terminated.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2017-002444-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002444-32.